+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 339 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating CGT9486 bezuclastinib in an open-label Phase 2 study for patients with Advanced Systemic Mastocytosis AdvSM, including Aggressive Systemic Mastocytosis ASM, Systemic Mastocytosis with an Associated Hematologic Neoplasm SM-AHN, and Mast Cell Leukemia MCL. The study aims to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of bezuclastinib as a single agent in these conditions. Participants receive bezuclastinib tablets orally, taken continuously in 28-day cycles. The study has two parts Part I focuses on identifying clinically active and tolerable doses of bezuclastinib, while Part II determines the drugs efficacy by measuring the modified IWG Objective Response Rate ORR and confirming the exposure-response relationship. Treatment and evaluation continue for up to 18 months. During the study, participants undergo assessments including laboratory tests, imaging to measure spleen and liver volume, and evaluation of mutation allele burden, serum tryptase, and histopathologic changes in blood and bone marrow. Safety is monitored through adverse event reporting. The study measures duration and time to response, progression-free survival, and overall survival. Participants are involved in regular monitoring throughout the treatment period extending up to 18 months.

Age: 18Years +All GendersPhase 2
42 locations
P

Actively Recruiting

Researchers are evaluating the imaging agent 64Cu-LNTH-1363S in patients with sarcomas or gastrointestinal tract GIT cancers to assess its safety, determine the best imaging dose and timing, and compare the imaging results with fibroblast activation protein FAP expression in tumor samples. This Phase 12a open-label study is divided into two parts and aims to better understand how this radiolabeled agent behaves in the body and how well it highlights tumors that express FAP. In Part 1, six patients with metastatic sarcomas will receive a fixed dose of 64Cu-LNTH-1363S to evaluate its distribution, radiation dose, and optimal imaging window during a one-day intervention, followed by a safety follow-up. In Part 2, approximately 20 patients with non-metastatic, operable sarcomas or GIT cancers scheduled for surgery will receive the optimal dose determined in Part 1 to study the correlation between imaging results and tissue FAP expression. Both parts include detailed cardiac monitoring to assess any changes in heart activity related to the agent. Participants will undergo screening before receiving the imaging agent, followed by serial PETCT scans at multiple timepoints on the intervention day to measure biodistribution and image quality. Tissue samples collected during surgery will be analyzed to compare with imaging findings. Safety and tolerability will be monitored through follow-up visits, ECGs, and phone contact. The total study duration varies from about three weeks for Part 1 to up to 11 weeks for Part 2, including surgery and post-surgery sample collection.

Age: 15Years +All GendersPhase 1Phase 2
5 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of two drugs, 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA, in men with prostate cancer that has spread and no longer responds to hormone-lowering treatments. This study focuses on cancers that express a protein called PSMA and aims to find safe and effective dosing while monitoring how the drugs behave in the body. Participants will go through different study phases. In the initial dosimetry phase, a single dose of 200 MBq of 64Cu-SAR-bisPSMA is given. Later phases involve receiving multiple doses of 64Cu-SAR-bisPSMA or 67Cu-SAR-bisPSMA, with doses and number of administrations varying by phase and participant group. The dose escalation phase tests increasing doses of 67Cu-SAR-bisPSMA, followed by a cohort expansion phase with up to six doses of the recommended 67Cu-SAR-bisPSMA dose. During the study, participants will undergo PETCT scans to track drug distribution and dosimetry within 48 hours of dosing. Researchers will measure prostate-specific antigen PSA levels and radiographic responses over up to five years to evaluate treatment effects. Safety will be monitored through assessments of vital signs, ECGs, laboratory tests, and recording any adverse events. The total study duration can extend up to five years for long-term follow-up.

Age: 18Years +MALEPhase 1Phase 2
7 locations
S

Actively Recruiting

Researchers are evaluating the use of a PET isotope called Fluorine-18 18F attached to Choline in people suspected of having parathyroid adenoma who have negative or unclear results from the standard 99mTc Sestamibi SPECTCT scan. The study focuses on detecting parathyroid adenomas using this new imaging technique in a single-center, single-arm trial. Participants receive an intravenous injection of 18F Fluorocholine about 5 mCi with a 20% margin, followed 45 to 60 minutes later by a low dose CT scan from the skull base to mid-thighs. This is immediately followed by a static PET emission scan over the same area, aiming to locate parathyroid adenomas more effectively than the standard scan. During the study, participants undergo the PETCT imaging process once, and researchers measure the number of lesions detected within an hour after the scan. Safety is monitored through blood tests and heart monitoring prior to the scan. The total participation time is brief and focused on imaging and related assessments.

Age: 18Years +All GendersPhase 2Phase 3
1 location
E

Actively Recruiting

Researchers are studying a 12-week early intervention program designed for preschool children with developmental disorders, including Autism Spectrum Disorder, neurogenetic disorders, or intellectual disability. The goal is to evaluate how this program helps improve social communication skills in these children by comparing changes in social responsiveness and related behaviors before and after treatment. The intervention involves 12 hours per week over 12 weeks, delivered either in an intensive center-based preschool setting or at home. This behavioral program focuses on structured activities aimed at addressing social communication deficits in young children with developmental disorders. Participants will be assessed at the start and end of the 12-week program using parent-rated questionnaires measuring social responsiveness, repetitive behaviors, social dimensions, adaptive behaviors, sensory profiles, and self-efficacy. The study tracks changes in these areas to understand the programs effects, with continued monitoring until the studys completion in 2034. Children and their families will engage regularly in the intervention and assessments during this period.

Age: 2Years - 5YearsAll GendersPhase Not Applicable
1 location
T

Actively Recruiting

Researchers are investigating a combination therapy of BNT326 and pumitamig for adults with advanced or metastatic non-small cell lung cancer NSCLC that has either relapsed, progressed, or is treatment-nafve. The study includes multiple parts to find the best dose levels, assess safety and tolerability, and evaluate how well the therapy works to shrink tumors in this patient population. The trial is open-label and conducted across multiple sites, focusing on participants with confirmed advanced NSCLC where no curative treatment is available. The study consists of three parts Part 1 focuses on finding safe dose combinations of BNT326 with pumitamig Part 2a expands the dose evaluation to examine preliminary effectiveness and safety and Part 2b randomizes participants to optimize dosing and assess the contribution of each therapy component. Participants with prior treatment and those who are treatment-nafve are enrolled in different cohorts. Treatment is administered via intravenous infusion, and dose levels for Part 2b are determined based on earlier results. Participants undergo a screening period before starting treatment, which can continue for up to 24 months or until disease progression or unacceptable side effects occur. Follow-up periods monitor safety, efficacy, and long-term survival, with total involvement expected to last about 36 months unless ongoing benefit warrants extended treatment. Researchers evaluate dose-limiting toxicities, adverse events, tumor response rates, progression-free survival, and pharmacokinetics to understand treatment effects and participant outcomes.

Age: 18Years +All GendersPhase 1Phase 2
86 locations
P

Actively Recruiting

Researchers are evaluating KK2223 in adults with relapsed or refractory peripheral T cell lymphoma PTCL or cutaneous T cell lymphoma CTCL. This Phase 1, multicenter, open-label, non-randomized study aims to understand the safety, tolerability, pharmacokinetics, and pharmacodynamics of KK2223 in these lymphoma subtypes. The study has two parts a dose-escalation phase and a backfill phase to further assess dosing and safety. Participants will receive KK2223 by intravenous infusion. In Part 1, the study uses a dose-escalation design to find the maximum tolerated dose by gradually increasing dose levels. Part 2 collects additional data at doses found to be tolerable in Part 1, with cohort sizes and dose levels based on earlier results. Enrollment priority may be given to participants in the dose-escalation phase. Throughout the study, participants will undergo regular assessments including safety monitoring for adverse events, blood tests to measure drug levels and immune response, and evaluations of anti-tumor activity. Researchers will monitor treatment effects and drug behavior over approximately 1.5 years. Participants must comply with study procedures and provide tumor tissue samples for evaluation. The study involves periodic visits and monitoring to assess outcomes like safety, drug concentration, and tumor response.

Age: 18Years +All GendersPhase 1
22 locations
P

Actively Recruiting

Researchers are evaluating the safety and effects of a single oral dose of HB-2121 in adults suspected of having celiac disease. This phase 1 clinical trial aims to understand any side effects after taking HB-2121 and how the drug interacts with the small intestine. The study focuses on adult participants undergoing standard diagnostic procedures for suspected celiac disease. Participants will receive a one-time oral dose of 250 mg HB-2121 four hours before their scheduled esophagogastroduodenoscopy EGD. The study includes a total of six visits four in-person clinic visits for health checkups, lab tests, and monitoring, as well as two remote visits involving safety lab assessments. Participants will also complete a daily questionnaire for seven days to report symptoms and health status. Throughout the study, researchers will monitor participants for 30 days post-dose to observe the frequency and severity of any adverse events. They will assess how the drug affects the small intestine by measuring specific markers such as fluorescence intensity and tissue characteristics from biopsy samples taken during the EGD. Safety labs, physical exams, and symptom questionnaires will be used to track participant health and drug effects during the trial period.

Age: 18Years +All GendersPhase 1
1 location
L

Actively Recruiting

This long-term follow-up observational study is designed to assess the safety of a gene-modified regulatory T cell Treg therapeutic in individuals who have previously received this treatment. It focuses on evaluating the type, severity, and possible causes of delayed adverse events over an extended period. The study enrolls adults aged 18 to 71 who have been treated in earlier clinical trials involving the gene-modified Treg therapy. Participants will undergo safety monitoring procedures including completing health questionnaires, routine physical exams, and reviews of medical history and medication use. Biospecimens such as blood and tissue samples will be collected at scheduled visits to detect any delayed adverse events related to the prior cell therapy. The study is planned to last up to 15 years following the initial dose received in parent treatment protocols. Throughout the study, participants will attend visits according to a set schedule for assessments and monitoring. Researchers will measure the incidence of delayed adverse events possibly linked to the gene-modified Treg therapeutic and track persistence of the therapy, replication competent lentivirus incidence, and mortality. The studys long duration allows careful observation of safety outcomes related to the treatment over time.

Age: 18Years - 71YearsAll Genders
10 locations
L

Actively Recruiting

Researchers are studying the long-term safety of ciltacabtagene autoleucel cilta-cel, a CAR-T therapy targeting B-cell maturation antigen in patients previously treated for multiple myeloma. The goal is to collect data on delayed side effects and better understand the long-term risks associated with cilta-cel treatment. This study is a phase 4 trial sponsored by Janssen Research & Development, LLC. Participants in this study do not receive any new treatment. Instead, the study monitors individuals who had previously received cilta-cel in company-sponsored clinical trials. The study is divided into two phases the first five years after the last cilta-cel dose, and years six to fifteen after that dose. Follow-up evaluations are conducted at least once per year to check for any delayed adverse events. During the study, participants undergo safety assessments including reviews of adverse events, laboratory tests, physical and neurological examinations. Researchers track outcomes such as new malignancies, neurological or autoimmune disorders, serious infections, and other serious adverse events over a period of up to 15 years. This long-term follow-up helps characterize the safety profile of cilta-cel after treatment completion.

Age: 18Years +All GendersPhase 4
50 locations

1-10 of 339

1